90K (Mac-2 BP) and galectins in tumor progression and metastasis

Glycoconjugate Journal

Volumn 19, Issue 7-9, 2002, Pages 551-556

  Grassadonia, Antonino ^a   Tinari, Nicola ^a   Iurisci, Ida ^a   Piccolo, Enza ^a   Cumashi, Alba ^a   Innominato, Pasquale ^a   D'Egidio, Maurizia ^a   Natoli, Clara ^a   Piantelli, Mauro ^a   Iacobelli, Stefano ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cancer; Galectins; Mac 2 BP; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; GALECTIN; GALECTIN 1; GALECTIN 3; GALECTIN 7; GLYCOPROTEIN; LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER SURVIVAL; CELL ADHESION; CELL TRANSFORMATION; EXTRACELLULAR MATRIX; GLYCOSYLATION; HUMAN; LYMPHOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; TUMOR GROWTH;

CARRIER PROTEINS; DISEASE PROGRESSION; GALECTINS; GLYCOPROTEINS; HUMANS; LIPOPROTEINS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 12144291347     PISSN: 02820080     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:GLYC.0000014085.00706.d4     Document Type: Review

References (61)

1. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A, Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family, Cancer Res 57, 5272-6 (1997).
2. Kasai K, Hirabayashi J, Galectins: A family of animal lectins that decipher glycocodes. J Biochem 119, 1-8 (1996).
3. Kim HR, Lin HM, Biliran H, Raz A, Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells, Cancer Res 59, 4148-54 (1999).
4. Matarrese P, Fusco O, Tinari N, Natoli C, Liu FT, Semeraro ML, Malorni W, Iacobelli S, Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85, 545-54 (2000).
5. Yang RY, Hsu DK, Liu FT, Expression of galectin-3 modulates T-cell growth and apoptosis, Proc Natl Acad Sci USA 93, 6737-42 (1996).
6. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A, Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family, Cancer Res 57, 5272-6 (1997).
7. Matarrese P, Tinari N, Semeraroa ML, Natolib C, Iacobelli S, Malorni W, Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis, FEBS Lett 473, 311-5 (2000).
8. Inohara H, Akahani S, Raz A, Galectin-3 stimulates cell proliferation, Exp Cell Res 245, 294-302 (1998).
9. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A, Galectin-3 induces endothelial cell morphogenesis and angiogenesis, Am J Pathol 156, 899-909 (2000).
10. Woo HJ, Shaw LM, Messier JM, Mercurio AM, The major non-integrin laminin binding protein of macrophages is identical tocarbohydrate binding protein 35 (Mac-2), J Biol Chem 265, 7097-9 (1990).
11. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins, Structure and function of a large family of animal lectins, J Biol Chem 269, 20807-10 (1994).
12. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A, Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain, J Biol Chem 268, 14245-9 (1993).
13. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, et al., The secreted tumor-associated antigen 90K is a potent immune stimulator, J Biol Chem 269, 18401-7 (1994).
14. Iacobelli S, Arno E, D'Orazio A, Coletti G, Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer, Cancer Res 46, 3005-10 (1986).
15. Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT, Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation, Int J Cancer 91, 167-72 (2001).
16. Andre S, Pieters RJ, Vrasidas I, Kaltner H, Kuwabara I, Liu FT, Liskamp RM, Gabius HJ, Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to glycoproteins, lactose maxicluster, and cell surface glycoconjugates, Chembiochem 2, 822-30 (2001).
17. Resnick D, Pearson A, Krieger M, The SRCR superfamily: A family reminescent of the Ig superfamily, Trends Biochem Sci 19, 5-8 (1994).
18. Sasaki T, Brakebusch C, Engel J, Timpl R, Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin, EMBO J 17, 1606-13 (1998).
19. D'Ostilio N, Sabatino G, Natoli C, Ullrich A, Iacobelli S, 90K (Mac-2 BP) in human milk, Clin Exp Immunol 104, 543-6 (1996).
20. Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, Porcari P, Angelucci D, D'Egidio M, Levrero M, Iacobelli S, Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients, J Hepatol 25, 212-7 (1996).
21. Natoli C, Dianzani F, Mazzotta F, Balocchini E, Pierotti P, Antonelli G, Iacobelli S, 90K protein: A new predictor marker of disease progression in human immunodeficiency virus infection, J Acquir Immune Defic Syndr 6, 370-5 (1993).
22. Briggs NC, Natoli C, Tinari N, D'Egidio M, Goedert JJ, Iacobelli S, A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1 + homosexual men, AIDS Res Hum Retroviruses 9, 811-6 (1993).
23. Pelliccia P, Natoli C, Petitti MT, Verrotti A, Chiarelli F, Iacobelli S, Elevated levels of circulating immunostimulatory 90K in Henoch-Schoenlein purpura, J Clin Immunol 19, 143-7 (1999).
24. Iacobelli S, Arno E, Sismondi P, Natoli C, Gentiloni N, Scambia G, Giai M, Cortese P, Panici PB, Mancuso S, Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients, Breast Cancer Res Treat 11, 19-30 (1988).
25. Scambia G, Panici PB, Baiocchi G, Perrone L, Iacobelli S, Mancuso S, Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer, Anticancer Res 8, 761-4 (1988).
26. Natoli C, Garufi C, Tinari N, D'Egidio M, Lesti G, Gaspari LA, Visini R, Iacobelli S, Dynamic test with recombinant interferon-alpha-2b: Effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease, Br J Cancer 67, 564-7 (1993).
27. Iacobelli S, Sismondi P, Giai M, D'Egidio M, Tinari N, Amatetti C, Di Stefano P, Natoli C, Prognostic value of a novel circulating serum 90K antigen in breast cancer, Br J Cancer 69, 172-6 (1994).
28. Rea A, Calmieri G, Tinari N, Natoli C, Tagliaferro P, Morabito A, Grassadonia A, Bianco AR, Iacobelli S, 90K is a serum marker of poor prognosis in non-Hodgikin's lymphoma patients, Oncol Rep 1, 723-5 (1994).
29. Zeimet AG, Natoli C, Herold M, Fuchs D, Windbichler G, Daxenbichler G, Iacobelli S, Dapunt O, Marth C, Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer, Int J Cancer 68, 34-8 (1996).
30. Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA, Sacco R, Mucilli F, Ullrich A, Iacobelli S, Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancerpatients, Cancer Res 62, 2535-9 (2002).
31. Fornarini B, D'Ambrosio C, Natoli C, Tinari N, Silingardi V, Iacobelli S, Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo, Blood 96, 3282-5 (2000).
32. Zhang DS, Jiang WQ, Li S, Zhang XS, Mao H, Chen XQ, Li YH, Zhan J, Wang FH, Predictive significance of serum 90K/Mac-2BP on chemotherapy response in non-Hodgkin's lymphoma, Ai Zheng 22, 870-3 (2003).
33. Raz A, Lotan R, Endogenous galactoside-binding lectins: A new class of functional tumor cell surface molecules related to metastasis, Cancer Metastasis Rev 6, 433-52 (1987).
34. Raz A, Lotan R, Lectin-like activities associated with human and murine neoplastic cells, Cancer Res 41, 3642-7 (1981).
35. Raz A, Zhu DG, Hogan V, Shah N, Raz T, Karkash R, Pazerini G, Carmi P, Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis, Int J Cancer 46, 871-7 (1990).
36. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, Raz A, Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3, Gastroenterology 115, 287-96 (1998).
37. Inufusa H, Nakamura M, Adachi T, Aga M, Kurimoto M, Nakatani Y, Wakano T, Miyake M, Okuno K, Shiozaki H, Yasutomi M, Role of galectin-3 in adenocarcinoma liver metastasis, Int J Oncol 19, 913-9 (2001).
38. Song YK, Billiar TR, Lee YJ, Role of galectin-3 in breast cancer metastasis: Involvement of nitric oxide, Am J Pathol 160, 1069-75 (2002).
39. Honjo Y, Nangia-Makker P, Inohara H, Raz A, Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells, Clin Cancer Res 7, 661-8 (2001).
40. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S, Concentrations of galectin-3 in the sera of normal controls and cancer patients, Clin Cancer Res 6, 1389-93 (2000).
41. Xu XC, el-Naggar AK, Lotan R, Differential expression of galectin-1 and galectin-3 in thyroid tumors: Potential diagnostic implications, Am J Pathol 147, 815-22 (1995).
42. Chiariotti L, Berlingieri MT, Battaglia C, Benvenuto G, Martelli ML, Salvatore P, Chiappetta G, Bruni CB, Fusco A, Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors, Int J Cancer 64, 171-5 (1995).
43. Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotchi J, Zick Y, Salmon I, Gabius HJ, Kiss R, Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration, Brain Pathol 11, 12-26 (2001).
44. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, Tahara E, Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas, Int J Cancer 56, 474-80 (1994).
45. Schoeppner HL, Raz A, Ho SB, Bresalier RS, Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon, Cancer 75, 2818-26 (1995).
46. Sanjuan X, Fernandez PL, Castells A, Castronovo V, van den Brule F, Liu FT, Cardesa A, Campo E, Differential expression of galectin 3 and galectin 1 in colorectal cancer progression, Gastroenterology 113, 1906-15 (1997).
47. Schaffert C, Pour PM, Chaney WG, Localization of galectin-3 in normal and diseased pancreatic tissue, Int J Pancreatol 23, 1-9 (1998).
48. Berberat PO, Friess H, Wang L, Zhu Z, Bley T, Frigeri L, Zimmermann A, Buchler MW, Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer, J Histochem Cytochem 49, 539-49 (2001).
49. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT, Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma, Int J Cancer 81, 519-26 (1999).
50. Inohara H, Akahani S, Koths K, Raz A, Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion, Cancer Res 56(19), 4530-4 (1996).
51. Sato S, Hughes RC, Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin, J Biol Chem 267, 6983-90 (1992).
52. Jallal B, Powell J, Zachwieja J, Brakebusch C, Germain L, Jacobs J, Iacobelli S, Ullrich A, Suppression of tumor growth in vivo by local and systemic 90K level increase, Cancer Res 55, 3223-7 (1995).
53. Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R, Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer, Urol Res 27, 362-7 (1999).
54. Castronovo V, Van Den Brule FA, Jackers P, Clausse N, Liu FT, Gillet C, Sobel ME, Decreased expression of galectin-3 is associated with progression of human breast cancer, J Pathol 179, 43-8 (1996).
55. Idikio H, Galectin-3 expression in human breast carcinoma: Correlation with cancer histologic grade, Int J Oncol 12, 1287-90 (1998).
56. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME, Castronovo V, Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma, Hum Pathol 27, 1185-91 (1996).
57. Castronovo V, Campo E, van den Brule FA, Claysmith AP, Cioce V, Liu FT, Fernandez PL, Sobel ME, Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma, J Natl Cancer Inst 84, 1161-9 (1992).
58. Lotz MM, Andrews CW, Jr, Korzelius CA, Lee EC, Steele GD, Jr, Clarke A, Mercurio AM, Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma, Proc Natl Acad Sci USA 90, 3466-70 (1993).
59. Choufani G, Nagy N, Saussez S, Marchant H, Bisschop P, Burchert M, Danguy A, Louryan S, Salmon I, Gabius HJ, Kiss R, Hassid S, The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers, Cancer 86, 2353-63 (1999).
60. Lahm H, Andre S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, Wolf E, Gabius HJ, Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures, J Cancer Res Clin Oncol 127, 375-86 (2001).
61. Piantelli M, Iacobelli S, Almadori G, Iezzi M, Tinari N, Natoli C, Cadoni G, Lauriola L, Ranelletti F, Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma, J Clin Oncol 20, 3850-6 (2002).